Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $12B | $11.02B | +8.90% |
Cost of Revenue | $1.65B | $1.53B | +7.89% |
Operating Income | $4.17B | $-232.9M | +1891.88% |
Net Income | $3.95B | $-535.6M | +838.09% |
EPS (Basic) | $15.46 | $-2.08 | +843.27% |
EPS (Diluted) | $15.32 | $-2.08 | +836.54% |
SG&A Expense | $1.75B | $1.46B | +19.72% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $25.64B | $22.53B | +13.80% |
Current Assets | $11.2B | $9.6B | +16.72% |
Total Liabilities | $6.98B | $6.12B | +13.94% |
Current Liabilities | $3.86B | $3.56B | +8.32% |
Stockholders' Equity | $18.67B | $16.41B | +13.75% |
Cash & Equivalents | $5.08B | $4.57B | +11.27% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $3.63B | $-492.6M | +837.19% |
Investing Cash Flow | $-945.4M | $-3.77B | +74.92% |
Financing Cash Flow | $-2.26B | $-1.49B | -51.27% |
Share Buybacks | $2.02B | $1.18B | +71.39% |
D&A | $209.8M | $207.2M | +1.25% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Margin | 34.8% | -2.1% | +36.89% |
Net Margin | 32.9% | — | — |
ROE | 21.2% | — | — |
ROA | 15.4% | — | — |
Current Ratio | $2.901 | — | — |
Debt to Equity | $0.374 | — | — |
VRTX achieved a significant turnaround in 2025 with strong revenue growth and a return to profitability, highlighted by a substantial increase in net income and EPS.
VRTX experienced an 8.9% increase in revenue, driven by strong sales across its product portfolio.
Source: Source: 10-K Income Statement, p.1
Operating income increased by 1891.9%, reflecting improved operational efficiency and cost management.
Source: Source: 10-K Income Statement, p.1
Operating cash flow turned positive, increasing by 837.2%, indicating better cash management and operational performance.
Source: Source: 10-K Cash Flow, p.1
VRTX's revenue is heavily dependent on a few key products, which could be impacted by market competition or regulatory changes.
Source: Source: General Industry Knowledge
Unlock 2 more detailed risk analysis
Upgrade to unlockOther companies in Biotechnology